A statement released earlier today by Zacks Investment Research about Celldex Therapeutics, Inc. (NASDAQ:CLDX) raises the target price to $5.00
- Updated: November 28, 2016
Only yesterday Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded -7.79% lower at $4.43. CLDX’s 50-day average is $3.78 and its two hundred day average is $4.09. The last stock close price is up -0.01% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time period. 1,601,025 shares of CLDX traded hands, down from an average trading volume of 2,368,350
Celldex Therapeutics, Inc. (NASDAQ:CLDX) had its stock price target increased to $5.00 by Zacks Investment Research in a report released Monday November 28, 2016. The increased price target implies a potential upside of 0.13% from the company's previous stock price.
Recent Performance Chart
Celldex Therapeutics, Inc. has 52 week low of $2.85 and a 52 week high of $18.56 and has a market capitalization of $0.
In addition to Zacks Investment Research reporting its target price, a total of 11 brokers have issued a report on the stock. The consensus target price is $31.27 with 6 brokers rating the stock a strong buy, 3 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Celldex Therapeutics, Inc. (NASDAQ:CLDX)
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII). Its Glembatumumab vedotin (CDX-011) is a targeted antibody-drug conjugate for the treatment of metastatic melanoma. Its Varlilumab (CDX-1127) is an immune modulating antibody that is designed to enhance a patient's immune response against their cancer. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.